The New England Journal of Medicine, NEJM, published results from Novo Nordisk’s (NVO) phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes. REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo. These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s, ADA, 85th Scientific Sessions and published in NEJM. When adhering to treatment, weight loss of greater than or equal to 5%, greater than or equal to20%, greater than or equal to25%, and greater than or equal to30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk price target lowered to $90 from $110 at Argus
- Eli Lilly Stock (LLY) Beefs Up as India Watches its Weight
- Eli Lilly (LLY) to Offer Higher Doses of Its Weight-Loss Drug on Website
- Prothena announces corporate restructuring, cuts 63% of workforce
- LifeMD price target raised to $18 from $15 at BTIG